Barbara Kaproń

Dr. Barbara Kaproń

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
BKBarbara Kaproń
Barbara Kaproń
JŁJarogniew J. Łuszczki
Jarogniew J. Łuszczki
APAnita Płazińska
Anita Płazińska
ASAgata Siwek
Agata Siwek
TKTadeusz Karcz
Tadeusz Karcz
TPTomasz Plech
Tomasz Plech

1 June 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TPTomasz Plech
Tomasz Plech
BKBarbara Kaproń
Barbara Kaproń
APAgata Paneth
Agata Paneth
UKUrszula Kosikowska
Urszula Kosikowska
Anna MalmAnna Malm
Anna Malm
Małgorzata Polz-DacewiczMałgorzata Polz-Dacewicz
Małgorzata Polz-Dacewicz

1 January 2020 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
BKBarbara Kaproń
Barbara Kaproń
RCRobert Czarnomysy
Robert Czarnomysy
MWMariusz Wysokiński
Mariusz Wysokiński
RARudolf Andrys
Rudolf Andrys
KMKamil Musilek
Kamil Musilek
TPTomasz Plech
Tomasz Plech
There are numerous studies supporting the contribution of oxidative stress to the pathogenesis of epilepsy. Prolonged oxidative stress is associated with the overexpression of ATP-binding cassette transporters, which results in antiepileptic drugs resistance. During our studies, three 1,2,4-triazole-3-thione derivatives were evaluated for the antioxidant activity and anticonvulsant effect in the 6 Hz model of pharmacoresistant epilepsy. The investigated compounds exhibited 2-3 times more potent anticonvulsant activity than valproic acid in 6 Hz test in mice, which is well-established preclinical model of pharmacoresistant epilepsy. The antioxidant/ROS scavenging activity was confirmed in both single-electron transfer-based methods (DPPH and CUPRAC) and during flow cytometric analysis of total ROS activity in U-87 MG cells. Based on the enzymatic studies on human carbonic anhydrases (CAs), acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), one can assume that the herein investigated drug candidates will not impair the cognitive processes mediated by CAs and will have minimal off-target cholinergic effects.

1 October 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TPTomasz Plech
Tomasz Plech
BKBarbara Kaproń
Barbara Kaproń
JŁJarogniew J. Łuszczki
Jarogniew J. Łuszczki
APAgata Paneth
Agata Paneth
ASAgata Siwek
Agata Siwek
GNGabriel Nowak
Gabriel Nowak

10 December 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ESElżbieta Studzińska-Sroka
Elżbieta Studzińska-Sroka
Aleksandra Majchrzak-CelińskaAleksandra Majchrzak-Celińska
Aleksandra Majchrzak-Celińska
Przemysław ZalewskiPrzemysław Zalewski
Przemysław Zalewski
Dominik SzwajgierDominik Szwajgier
Dominik Szwajgier
EBEwa Baranowska-Wójcik
Ewa Baranowska-Wójcik
Judyta Cielecka-PiontekJudyta Cielecka-Piontek
Judyta Cielecka-Piontek
Lichens are a source of chemical compounds with valuable biological properties, structurally predisposed to penetration into the central nervous system (CNS). Hence, our research aimed to examine the biological potential of lipophilic extracts of Parmelia sulcata, Evernia prunastri, Cladonia uncialis, and their major secondary metabolites, in the context of searching for new therapies for CNS diseases, mainly glioblastoma multiforme (GBM). The extracts selected for the study were standardized for their content of salazinic acid, evernic acid, and (−)-usnic acid, respectively. The extracts and lichen metabolites were evaluated in terms of their anti-tumor activity, i.e., cytotoxicity against A-172 and T98G cell lines and anti-IDO1, IDO2, TDO activity, their anti-inflammatory properties exerted by anti-COX-2 and anti-hyaluronidase activity, antioxidant activity, and anti-acetylcholinesterase and anti-butyrylcholinesterase activity. The results of this study indicate that lichen-derived compounds and extracts exert significant cytotoxicity against GBM cells, inhibit the kynurenine pathway enzymes, and have anti-inflammatory properties and weak antioxidant and anti-cholinesterase properties. Moreover, evernic acid and (−)-usnic acid were shown to be able to cross the blood-brain barrier. These results demonstrate that lichen-derived extracts and compounds, especially (−)-usnic acid, can be regarded as prototypes of pharmacologically active compounds within the CNS, especially suitable for the treatment of GBM.

31 July 2014 in Molecules
Verified
Journal Article
Open access
PDF file
TPTomasz Plech
Tomasz Plech
BKBarbara Kaproń
Barbara Kaproń
JŁJarogniew J. Łuszczki
Jarogniew J. Łuszczki
Monika WujecMonika Wujec
Monika Wujec
APAgata Paneth
Agata Paneth
GNGabriel Nowak
Gabriel Nowak
The anticonvulsant activity of several 1,2,4-triazole-3-thione derivatives on mouse maximal electroshock-induced seizures was tested in this study. Characteristic features of all active compounds were rapid onset of action and long lasting effect. Structure-activity observations showed that the probability of obtaining compounds exerting anticonvulsant activity was much higher when at least one of the phenyl rings attached to 1,2,4-triazole nucleus had a substituent at the para position. The obtained results, moreover, permit us to conclude that despite the structural similarity of loreclezole (second-generation anticonvulsant drug) and the titled compounds, their anticonvulsant activity is achieved via completely different molecular mechanisms.